Testing how blood-clotting is managed in hemophilia with inhibitors
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study looks at different ways to help blood clot in people with hemophilia who have developed inhibitors (proteins that stop standard clotting treatments from working). It may help doctors choose the safest, most effective clotting approach for these situations.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your legal guardian) can give informed consent to join the study
- You fit the study’s main group (people with hemophilia who have inhibitors)
- You must be at least 7 years old
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a clotting factor product called PCC (prothrombin complex concentrate) to treat bleeding episodes in people with hemophilia A who have developed inhibitors. It's for those who are 12–65 and have frequent joint bleeds.
This study looks at how often people with hemophilia A develop inhibitors (antibodies that block the effectiveness of factor VIII) after using Coageight, a factor VIII replacement therapy. It may help understand the safety of this treatment.
This study looks at how prophylactic treatment for hemophilia affects your daily life, sleep, and feelings about your health. It compares different types of clotting factor concentrates to see if one is easier to manage than the other.
This study collects real-world information on how well a personalized clotting-factor plan helps people with hemophilia A get rid of inhibitors. It may help doctors refine treatment for patients who develop antibodies that block factor therapy.
This study tests whether KN057, a new preventive medicine, is safe for males with hemophilia A or B. It aims to help prevent bleeding episodes without causing unwanted blood clots.
This trial tests a new drug called KN057 for people with severe hemophilia A or moderate-to-severe hemophilia B, whether or not they have developed inhibitors (antibodies that block standard treatments). The goal is to see if it can help prevent or treat bleeding episodes.
Hear when a new Hemophilia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.